Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Real-world outcomes of 177Lu-PSMA-617 in mCRPC

Hannah McManus, MD, Duke Cancer Institute, Duke University School of Medicine, Durham, NC, briefly discusses the novel radiopharmaceutical lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) as an excellent treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Summarizing a recent paper assessing real-world clinical outcomes of treatment with 177Lu-PSMA-617 for mCRPC, Dr McManus notes the highly promising prostate specific antigen (PSA) response rates. Remarkably, a significant proportion of patients demonstrated a PSA50 and PSA90 response, demonstrating the clinical efficacy of 177Lu-PSMA-617 as an effective treatment for patients with mCRPC. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.